This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mutka, S. C. Articles by Murli, S. Search for Related Content PubMed PubMed Citation Articles by Mutka, S. C. Articles by Murli, S.

Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivo

Kosan Biosciences, Inc., Hayward, California

Requests for reprints: Sarah C. Mutka, N30 Pharmaceuticals, 3122 Sterling Circle, Boulder, CO 80301. Phone: 720-945-7723; Fax: 303-440-8399; E-mail: sarah.mutka{at}n30pharma.com.

Key Words: CRM1 • leptomycin B • nuclear export • p53 • cancer

The export protein CRM1 is required for the nuclear export of a wide variety of cancer-related "cargo" proteins including p53, c-Abl, and FOXO-3A. Leptomycin B (LMB) is a highly specific inhibitor of CRM1 with significant in vitro potency but limited in vivo efficacy due to toxicity. We now report a series of semisynthetic LMB derivatives showing substantially improved therapeutic windows. Exposure of cancer cells to these compounds leads to a rapid and prolonged block of nuclear export and apoptosis. In contrast to what is observed in cancer cells, these agents induce cell cycle arrest, but not apoptosis, in normal lung fibroblasts. These new nuclear export inhibitors (NEI) maintain the high potency of LMB, are up to 16-fold better tolerated than LMB in vivo, and show significant efficacy in multiple mouse xenograft models. These NEIs show the potential of CRM1 inhibitors as novel and potent anticancer agents. [Cancer Res 2009;69(2):510–7]

This article has been cited by other articles:

				J. G. Turner, D. C. Marchion, J. L. Dawson, M. F. Emmons, L. A. Hazlehurst, P. Washausen, and D. M. Sullivan Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition Cancer Res., September 1, 2009; 69(17): 6899 - 6905. [Abstract] [Full Text] [PDF]